Tirzepatide (Zepbound): The dual GIP/GLP-1 agonist approved for chronic weight management, showing even greater weight loss efficacy than semaglutide
We showed that the rats ate less, and that the microspheres activated the hypothalamus the brains appetite control center, says Hamaker, who has been at Purdue since 1992
Reconstituted at 2-8C, use within 60 days
Use an insulin syringe, inject into a pinch of skin at the abdomen or thigh, and rotate injection sites to avoid localized reactions
I want people to know that life after Mounjaro can be sustainable as well, she said
Fatigue affects 15-30% of patients starting tirzepatide, typically emerging within the first 4-8 weeks as the body adjusts to slowed gastric emptying and GLP-1 receptor activation